Moleculin Biotech (MBRX) Interest Coverage Ratio (2016 - 2026)
Moleculin Biotech (MBRX) posted quarterly Interest Coverage Ratio of 183.73 for Q4 2025, down 7.87% year-over-year from 199.42 in Q4 2024, and down 24.44% quarter-over-quarter from 147.65 in Q3 2025.
Moleculin Biotech (MBRX) Interest Coverage Ratio (2016 - 2026) Analysis & Trends
Moleculin Biotech's Interest Coverage Ratio history runs 10 years deep, the most recent figure standing at 183.73 for Q4 2025.
- In Q4 2025, Interest Coverage Ratio fell 7.87% year-over-year to 183.73; the TTM figure through Dec 2025 stood at 157.87 (up 14.07% YoY), while the FY2025 annual figure was 0.57, up 16.77% from the prior year.
- Interest Coverage Ratio for Q4 2025 stood at 183.73, down from 147.65 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 146.67 in Q2 2025, with the low at 432.57 in Q3 2022.
- The 5-year median for Interest Coverage Ratio is 177.49 (2021), against an average of 199.77.
- The sharpest annual moves came in 2021 and 2023: Interest Coverage Ratio sank 525.51% in 2021, then jumped 59.56% in 2023.
- Moleculin Biotech's Interest Coverage Ratio stood at 148.71 in 2021, then slipped by 24.72% to 185.47 in 2022, then tumbled by 92.35% to 356.76 in 2023, then jumped by 52.26% to 170.33 in 2024, then retreated by 7.87% to 183.73 in 2025.
- Business Quant data shows MBRX's Interest Coverage Ratio at 183.73 in Q4 2025, 147.65 in Q3 2025, and 146.67 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.00 Bn | 132.14 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 65.24 Bn | 60.06 Bn | 1.37 Bn | - |
| 4 | Moderna | 62.41 Bn | 57.27 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.18 Bn | 27.88 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.93 Bn | 10.54 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 1.42 |
| 10 | Moleculin Biotech | 3.30 Mn | 3.30 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -184.41 |
| Dec 31, 2025 | -183.73 |
| Sep 30, 2025 | -147.65 |
| Jun 30, 2025 | -146.67 |
| Mar 31, 2025 | -152.38 |
| Dec 31, 2024 | -170.33 |
| Sep 30, 2024 | -182.95 |
| Jun 30, 2024 | -162.76 |
| Mar 31, 2024 | -230.24 |
| Dec 31, 2023 | -356.76 |
| Sep 30, 2023 | -174.91 |
| Jun 30, 2023 | -168.71 |
| Mar 31, 2023 | -219.84 |
| Dec 31, 2022 | -185.47 |
| Sep 30, 2022 | -432.57 |
| Jun 30, 2022 | -212.40 |
| Mar 31, 2022 | -202.11 |
| Dec 31, 2021 | -148.71 |
| Sep 30, 2021 | -175.91 |
| Jun 30, 2021 | -162.26 |